News AVITA Medical, Inc.

Equities

RCEL

US05380C1027

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
8.27 ^USD	+4.42%		+0.12%	-39.72%

May. 14	Cantor Fitzgerald Trims Price Target on Avita Medical to $21 From $22, Maintains Overweight Rating	MT
May. 14	Piper Sandler Downgrades Avita Medical to Neutral From Overweight, Price Target is $9	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AVITA Medical to Host Investor Webinar Briefing	May. 16	AQ
Cantor Fitzgerald Trims Price Target on Avita Medical to $21 From $22, Maintains Overweight Rating	May. 14	MT
Piper Sandler Downgrades Avita Medical to Neutral From Overweight, Price Target is $9	May. 14	MT
Avita Medical Widens Q1 Loss as Sales, Marketing Expense Jumps; Shares Up 10%	May. 13	MT
Transcript : AVITA Medical, Inc., Q1 2024 Earnings Call, May 13, 2024	May. 13
AVITA Medical Reports First Quarter Financial Results	May. 13	AQ
AVITA Medical, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
Wilsons Downgrades Avita Medical to Market-Weight From Overweight; Price Target is AU$3.03	Apr. 17	MT
AVITA Medical to Announce First Quarter 2024 Financial Results	Apr. 15	AQ
BTIG Research Downgrades Avita Medical to Neutral From Buy	Apr. 11	MT
Avita Medical Lowers Q1 Revenue Guidance on Slower New Account Approvals	Apr. 10	MT
AVITA Medical Updates Expected First Quarter 2024 Revenue	Apr. 10	AQ
AVITA Medical, Inc. Revises Revenue Guidance for the First Quarter Ended March 31, 2024 and Full Year Fiscal 2024	Apr. 10	CI
AVITA Medical, Inc.(ASX:AVH) added to S&P/ASX All Ordinaries Index	Mar. 17	CI
AVITA Medical, Inc.(NasdaqCM:RCEL) added to S&P Biotechnology Select Industry Index	Mar. 17	CI
AVITA Medical Submits Additional RECELL GO PMA Supplement Information to US FDA	Feb. 29	MT
AVITA Medical Submits Response to FDA, Resuming Review Clock for RECELL GO PMA Supplement	Feb. 29	AQ
AVITA Medical to Present at TD Cowen 44th Annual Health Care Conference	Feb. 29	AQ
Transcript : AVITA Medical, Inc. - Special Call	Feb. 27
Piper Sandler Raises Price Target on Avita Medical to $21 From $19, Maintains Overweight Rating	Feb. 26	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News AVITA Medical, Inc.

Equities

RCEL

US05380C1027

Summary

Filters